Abstracts tagged "interleukins (IL) and spondylarthritis"

Abstract Number: 2064 • 2015 ACR/ARHP Annual Meeting
Increase in IL-31 Serum Level in Recent Onset Spondyloarthritis – Data from the DESIR Cohort
Nicolas Rosine Jr.¹, Adrien Etcheto², Anna Moltó³, Yassine Taoufik⁴, Houria Chavez⁴, Christian Roux⁵, Karine Briot⁵, Maxime Dougados⁶ and Corinne Miceli⁵, ¹Rheumatology Department, Hôpital Kremlin Bicêtre, Paris, France, ²Rheumatology B, Rheumatology B Department, Paris-Descartes University, Cochin Hospital, Paris, France, ³Paris Descartes University, Rheumatology Department, Cochin Hospital, AP-HP. INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité,, Paris, France, ⁴Biologic Immunology, Hopital Bicetre, Université Paris Sud, AP-HP, Kremlin Bicetre, France, ⁵Rheumatology B Department, Hôpital Cochin, Paris, France, ⁶Rheumatology B Department,, Paris-Descartes University, APHP, Cochin Hospital, Paris, France
Background/Purpose: IL-31 is a newly-described cytokine mainly produced by activated Th2 cells. IL-31 acts through IL31-RA and oncostatin heterodimeric receptors that activate STAT3 and STAT5. So far, IL31 has…
Abstract Number: 1741 • 2014 ACR/ARHP Annual Meeting
Anti-TNFα Treatment Increases IL-17A+ and IL-22+ T Cells in Spondyloarthritis Regardless of Concomittant Gut Inflammation
Thomas Andersen¹, René Østgård^1,2, Bent Deleuran^1,2, Malene Hvid³ and Henning Glerup⁴, ¹Dept. of Biomedicine, Aarhus University, Aarhus, Denmark, ²Dept. of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ³Dept. of Clinical Medicine, Aarhus University, Aarhus, Denmark, ⁴Dept. of Gastroenterology, Regional Hospital of Silkeborg, Silkeborg, Denmark
Background/Purpose The pro-inflammatory Th17 associated cytokines IL-17A and IL-22 have been proposed as important mediators of the inflammation seen in spondyloarthritis (SpA) and inflammatory bowel…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].